You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

313 Results
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Aug 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
May 2025
Drug
Other Name(s): Alunbrig®
Jul 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    brigatinib - For the treatment of anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer according to clinical criteria
Jul 2024
Regimen
Cancer Type:
Lung, 
Mesothelioma (Pleural)
Intent: Palliative
Oct 2024
Blog post
Recently, I provided opening remarks at an event that brought together various stakeholders to discuss opportunities and challenges presented by the...
Dec 2018
Blog post
This past spring I was giving a talk about the My CancerIQ risk assessment tool at one of Ontario’s largest primary care conferences. And, as I so...
Jan 2019
Guidelines and Advice
Status: In-Review
ID: RR 21-5
Version: n/a
Jan 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Sep 2025

Pages